ISTA Pharmaceuticals (ISTA) Tops Q3 EPS by 1c

October 30, 2008 9:04 AM EDT
ISTA Pharmaceuticals Inc. (Nasdaq: ISTA) reports Q3 EPS of $0.22, versus the consensus of a loss of $0.23. Revenues came in at $21.7 million, versus the consensus of $20.44 million.

ISTA Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, engages in the discovery, development, and marketing of therapies for inflammation, ocular pain, glaucoma, allergy, dry eye, vitreous hemorrhage, and diabetic retinopathy in the United States.

You May Also Be Interested In

Related Categories